This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

HCV 371

Shire Pharmaceuticals Group PLC

Drug Names(s): HCV 371

Description: HCV-371 is a novel nonnucleoside inhibitor of hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp).

Deal Structure: ViroPharma and Wyeth
In December 1999, ViroPharma and Wyeth engaged in a broad-based program designed to discover, develop and commercialize antiviral compounds to treat hepatitis C. Under the terms of the agreement, Wyeth pays a substantial portion of HCV research and development expenses incurred by ViroPharma. The companies will co-promote products resulting from the collaboration and share equally in profits from product sales in the U.S. and Canada. In the rest of the world, Wyeth will assume full responsibility for commercialization of products and will pay to ViroPharma royalties on product sales.

Wyeth and Pfizer
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The acquisition was completed in October 2009.

ViroPharma and Shire
In...See full deal structure in Biomedtracker

Partners: Pfizer Inc.

HCV 371 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug